CliffBio
biologic

Tubersol

Tuberculin, Purified Protein Derivative

Loss of exclusivityFebruary 2012projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines Canada Ltd.

Drug detail

Brand nameTubersol
Active ingredientTuberculin, Purified Protein Derivative
Strength5TU/.1ML
Dosage formInjection
RouteIntradermal
ModalityBiologic
FDA approvalFebruary 2000
Marketing statusRx

More from Sanofi Vaccines Canada Ltd.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tubersol patent cliff — loss of exclusivity February 2012 | CliffBio